xrad logo.jpg
XRad Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of XRD-0394 for Metastatic, Locally-Advanced or Recurrent Solid Tumors
August 25, 2021 07:30 ET | XRad Therapeutics, Inc.
-  Study to evaluate the safety and tolerability of XRD-0394 in combination with palliative radiation therapy -  Major milestone for the company with first asset reaching clinical development ...
Roots-Analysis-Logo.png
The glycosylation analysis services market is projected to reach nearly USD 2.5 billion by 2030, growing at an annualized rate of over 20%, claims Roots Analysis
August 18, 2021 09:30 ET | Roots Analysis
London, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Glycosylation Analysis Services Market, 2021 – 2030” report to its list of offerings. Profiling and in-depth...
Rubius_Logo.jpg
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
June 23, 2021 16:01 ET | Rubius Therapeutics
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Logo.png
Checkpoint Kinase Inhibitor Pipeline Analysis: Key Pharma Companies, and Emerging Therapies Offering New Horizons in Cancer Care
May 06, 2021 20:15 ET | DelveInsight Business Research LLP
Los Angeles, USA, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Kinase Inhibitor Pipeline Analysis: Key Pharma Companies, and Emerging Therapies Offering New Horizons in Cancer Care Several...
Rubius_Logo.jpg
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
April 09, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Cello logo (transparent background).png
Cello Therapeutics’ Platelet Membrane-Coated Nanoparticles Offer a Novel Platform for the Delivery of Immunotherapy in Cancer Treatment
March 31, 2021 22:57 ET | Cello Therapeutics, Inc.
SAN DIEGO, March 31, 2021 (GLOBE NEWSWIRE) -- Solid tumors comprise about 90% of all newly diagnosed cancer cases and cancer deaths according to an annual report from the National Cancer Institute....
Rubius_Logo.jpg
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
March 15, 2021 07:39 ET | Rubius Therapeutics
RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events  RTX-240 Promoted Trafficking of NK and T Cells into...
Rubius_Logo.jpg
Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
March 10, 2021 16:30 ET | Rubius Therapeutics
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Cend_ID_Color.jpg
Cend Therapeutics and Qilu Pharmaceutical Announce Partnership
February 16, 2021 08:00 ET | Cend Therapeutics Inc.
SAN DIEGO and JINAN, China, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc., a clinical-stage biotech company, and Qilu Pharmaceutical, a major Chinese pharmaceutical company, announced...
LOGO.png
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine
November 30, 2020 07:00 ET | Autolus Therapeutics plc
- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach...